A
Anja Seckinger
Researcher at Vrije Universiteit Brussel
Publications - 51
Citations - 2886
Anja Seckinger is an academic researcher from Vrije Universiteit Brussel. The author has contributed to research in topics: Multiple myeloma & AL amyloidosis. The author has an hindex of 20, co-authored 51 publications receiving 2533 citations. Previous affiliations of Anja Seckinger include University Hospital Heidelberg & Heidelberg University.
Papers
More filters
Journal ArticleDOI
Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood.
Wolfgang Wagner,Frederik Wein,Anja Seckinger,Maria Frankhauser,Ute Wirkner,Ulf Krause,Jonathon Blake,Christian Schwager,Volker Eckstein,Wilhelm Ansorge,Anthony D. Ho +10 more
TL;DR: The results have provided a foundation for a more reproducible and reliable quality control using genotypic analysis for defining MSC.
Journal ArticleDOI
Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load
Kai Neben,Anna Jauch,Thomas Hielscher,Jens Hillengass,Nicola Lehners,Anja Seckinger,Martin Granzow,Marc-Steffen Raab,Anthony D. Ho,Hartmut Goldschmidt,Dirk Hose +10 more
TL;DR: The high-risk chromosomal aberrations del(17p13), t(4;14), and +1q21 are adverse prognostic factors in SMM just as they are in active myeloma, independent of tumor mass.
Journal ArticleDOI
Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens
Tilmann Bochtler,U Hegenbart,Christina Kunz,Martin Granzow,Axel Benner,Anja Seckinger,Christoph Kimmich,Hartmut Goldschmidt,Anthony D. Ho,Dirk Hose,Anna Jauch,Stefan Schönland +11 more
TL;DR: iFISH results are important independent prognostic factors in AL amyloidosis, and bortezomib is less beneficial to patients harboring t(11;14), whereas it effectively alleviates the poor prognosis inherent to high-risk aberrations.
Journal ArticleDOI
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation
Kai Neben,Anna Jauch,Uta Bertsch,Christiane Heiss,Christiane Heiss,Thomas Hielscher,Anja Seckinger,Tina Mors,Nadine Muller,Jens Hillengass,Marc S. Raab,Anthony D. Ho,Dirk Hose,Hartmut Goldschmidt +13 more
TL;DR: These results have implications for risk-adapted management for patients with multiple myeloma undergoing high-dose chemotherapy followed by autologous stem cell transplantation and suggest that new treatment concepts are urgently needed for patients who belong to the poor prognosis group.
Journal ArticleDOI
Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.
Michelle M. McDonald,Michelle M. McDonald,Michaela R. Reagan,Michaela R. Reagan,Scott E. Youlten,Scott E. Youlten,Sindhu T. Mohanty,Anja Seckinger,Rachael L. Terry,Rachael L. Terry,Jessica A. Pettitt,Marija K. Simic,Tegan L. Cheng,Alyson Morse,Lawrence M. T. Le,David Abi-Hanna,David Abi-Hanna,Ina Kramer,Carolyne Falank,Heather Fairfield,Irene M. Ghobrial,Paul A. Baldock,Paul A. Baldock,David G. Little,Michaela Kneissel,Karin Vanderkerken,J. H. Duncan Bassett,Graham R. Williams,Babatunde O. Oyajobi,Dirk Hose,Tri Giang Phan,Tri Giang Phan,Peter I. Croucher,Peter I. Croucher +33 more
TL;DR: This study defines a therapeutic strategy superior to the current standard of care that will reduce fractures for patients with MM.